Key facts
- This treatment outlasts most postings. It is measured in years, and continuity across a move is a real risk to it.
- Two families, two mechanisms. Tamoxifen blocks the receptor; the aromatase inhibitors reduce the supply of oestrogen. Which is used depends substantially on menopausal status.
- Joint pain is the commonest reason people stop, it is a recognised class effect, and it is not imagined.
- Switching within the family is a real option, and the one most often not asked about.
- Bone thinning is the silent second effect, monitored rather than felt.
- On tamoxifen, unusual vaginal bleeding is always reported. No exceptions.
- This is the opposite of HRT. One replaces oestrogen; this removes or blocks it.
The hospital part finishes. The appointments thin out, the calendar clears, and people around you understandably treat it as over.
And you are holding a box of tablets you will take for years. Longer than this posting. Possibly longer than this country.
That is the shape of this treatment, and it is why the things that quietly end it early are worth naming.
Two ways to do the same job
Most breast cancers that are treated this way grow in response to oestrogen. So the treatment either stops oestrogen reaching the cancer, or reduces how much oestrogen exists.
| Family | On this site | What it does | Who it is usually for |
|---|---|---|---|
| Receptor blocker | tamoxifen | Occupies the oestrogen receptor so oestrogen cannot act on it | Often used before menopause, and sometimes after |
| Aromatase inhibitors | anastrozole, letrozole, exemestane | Reduce the body’s production of oestrogen after menopause | Generally after menopause |
That distinction is not a detail. The aromatase inhibitors work on the route the body uses to make oestrogen after the ovaries stop, which is why they are not simply interchangeable with tamoxifen and why menopausal status matters so much to the choice.
The National Cancer Centre Singapore sets out breast cancer and its treatments. What we list sits under oncology support, women’s health and breast cancer.
One clarification that matters in both directions. This is not hormone replacement therapy. HRT gives oestrogen back to relieve menopausal symptoms; this treatment removes or blocks it. Our article on HRT and menopause in Singapore covers the other one, and the confusion between them is worth actively avoiding.
The effect that ends treatment
Joint pain is the commonest reason people stop an aromatase inhibitor, and it is very often not reported before they do.
It arrives as stiffness, most noticeably in the hands in the morning: fingers that do not close properly, wrists that need a few minutes, sometimes knees and feet. The characteristic description is not sharp pain but a sudden ageing, as though a decade arrived over a few months.
Three things are worth knowing about it.
It is real and it is recognised, a class effect with a mechanism behind it rather than a coincidence or a complaint. Oestrogen is involved in tendons, joint lubrication and pain perception, so removing it has predictable consequences in places that have nothing to do with the breast.
It is not a sign the disease is progressing. That fear sits underneath a great deal of unreported symptom, and it is worth naming.
And switching within the family is a genuine option. The three aromatase inhibitors are not identical, and exemestane is chemically different from the other two. Moving between them, or in some situations to tamoxifen, is a real conversation with a real chance of improving things. It is also the option people least often think to ask about, because they assume the choice was made once and is final.
What is not the answer is quietly stopping, which is what happens most often, because the benefit of this treatment depends directly on taking it for the intended duration. A consultation that ends in an adjustment is worth immeasurably more than a decision made alone in a bathroom in March.
The silent one
Oestrogen slows the breakdown of bone. Removing it accelerates bone loss, and bone loss has no symptoms until something fractures.
So it is monitored. Bone assessment on a schedule your team decides, attention to calcium and vitamin D, weight-bearing and resistance exercise, sometimes specific treatment for the bone itself, and attention to preventing falls, since a fracture generally needs both a weak bone and an event.
Tamoxifen behaves differently on bone after menopause, which is one of the factors weighed when choosing between the two families.
Tamoxifen’s own list
Different mechanism, different profile.
Hot flushes are common. So are changes to periods in women who still have them.
There is a small increase in the risk of blood clots, which is why new leg swelling or pain, or breathlessness, is taken seriously rather than watched.
And there is an effect on the lining of the womb, which is why any unusual vaginal bleeding on tamoxifen is always reported, every time, without waiting to see whether it settles. Most causes turn out to be minor. The rule exists because the exceptions matter, and it is one of the few genuinely non-negotiable instructions in this article.
The years problem
This is where an audience that moves countries needs something the standard articles do not say.
A treatment lasting several years will, for many people here, span at least one relocation. The specific risks are worth naming: the hospital that holds your records is in another country; the brand you were established on may not exist here; a new oncologist starts without your history; and the gap while all that is arranged is a gap in treatment whose benefit depends on continuity.
What helps is unglamorous and works. Carry a written summary from your treating team, including the diagnosis, the treatment and the intended duration. Know the active ingredient rather than the brand, since the box changes name at borders; the medicine brand-name decoder covers that translation. Arrange the next clinic before the supply gets low rather than after. And if the manufacturer changes, mention it, rather than wondering privately whether the new tablets are working.
Also worth reading
For the equivalent treatment in prostate cancer, see hormone therapy for prostate cancer. For the treatment that does the opposite, see HRT and menopause in Singapore. For judging a generic and its maker, see buying generic medicines in Asia.
FAQ
Do the joint pains ever settle?
They often ease after the first several months, though not completely for everyone. Pain that persists and limits what you can do is a reason for a review and possibly a switch, not something to accept for years.
Can I take something for the joint pain?
Anti-inflammatories have their own risks over long periods and do not address the cause, so long-term self-medication is not the answer. Activity has better evidence than it deserves to have, counterintuitive as that is when you are stiff. Ask your team.
Is it safe to skip the odd day?
The benefit depends on taking it consistently over the intended period, so drifting is worth mentioning rather than managing privately. If something is making consistency hard, that is the useful thing to bring to the appointment.
Can I take supplements alongside this?
Tell your team everything you take, including herbal preparations and anything for menopausal symptoms. Some interact, and some contain plant oestrogens, which matters here more than it usually would.
Why is my treatment different from someone else’s?
Menopausal status, the type of cancer, other treatments and your own risk factors all feed into the choice. Comparing regimens with another patient is one of the more reliable ways to worry unnecessarily.
Sources
This article is general information, checked on 10 August 2026. It contains no doses, no schedules and no treatment protocols, and it is not a substitute for the team managing your care.
